Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-000947-26 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the safety and efficacy of multiple daily dosing of oral LFF571 in patients who have moderate Clostridium difficile infections.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LFF571 (POC) | Experimental |
| |
| Vancomycin (POC) | Active Comparator |
| |
| LFF571 Dose level 1 (cohort 2) | Experimental |
| |
| LFF571 Dose level 2 (cohort 2) | Experimental |
| |
| LFF571 Dose level 3 (cohort 2) | Experimental |
| |
| LFF571 Dose level 4 (cohort 2) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LFF571 | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| POC: Difference in clinical response rate of LFF571 compared to vancomycin in patients with moderate C. difficile infections at day 12/13. | Day 12/13 | |
| POC: Safety and tolerability of LFF571 | Safety assessments will include vital signs, laboratory tests, electrocardiograms (ECG), pharmacokinetic (PK) samples and adverse events. (Cohorts 1 and 2) | Day 12/13 |
| POC:Clinical response rates (clinical cure) of patients with moderate C. difficile infections to different LFF571 dose regimens and total daily doses (cohort 2). | Clinical cure is resolution or improvement of symptoms and signs of C. difficile infection such that additional or alternative antimicrobial therapy or other theraperutic intervention is not needed. In addition, patient must have absence of fever for two consecutive days and <3 non-lliquid stools per day for two consecutive days | Day 12/13 |
| Cohort 2: Clinical response rate (clinical cure) of LFF571 in patients with mild and moderate C. difficile infections to different LFF571 dose regimens and total daily doses administered orally for 10 days | Clinical cure is resolution or improvement of symptoms and signs of C. difficile infection such that additional or alternative antimicrobial therapy or other theraperutic intervention is not needed. In addition, patient must have absence of fever for two consecutive days and <3 non-lliquid stools per day for two consecutive days. | Day 12/13 |
| Cohort 2: Dose-response relationship of different dose regimens and total daily dose s of LFF571 | Day 12/13 | |
| Cohort 2: Safety and tolerability of LFF571 dose regimens and total daily doses administered orally for 10 days to C. difficile infected patients. |
| Measure | Description | Time Frame |
|---|---|---|
| POC: To evaluate the time to resolution of diarrhea during the treatment period for LFF571-treated patients (cohorts 1 and 2) | End of therapy | |
| POC: To evaluate the relapse rate within 30 days following completion of LFF571-treated patients (cohort 1) |
Not provided
Inclusion Criteria:
Received ≤24 hours of therapy effective for C. difficile infection prior to enrollment.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Palm Desert | California | 92211 | United States | ||
| Novartis Investigative Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25534727 | Derived | Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, Praestgaard J, Leeds JA, Blais J, Pertel P. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar;59(3):1435-40. doi: 10.1128/AAC.04251-14. Epub 2014 Dec 22. | |
| 25534724 |
| Label | URL |
|---|---|
| Results for CLFF571X2201from the Novartis Clinical Trials website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| Vancomycin (POC) | Drug |
|
Safety assessments will include vital signs, laboratory tests, electrocardiograms (ECG), pharmacokinetic (PK) samples and adverse events. |
| Day 12/13 |
| 30 days |
| POC: To evaluate the sustained response and relapse rate within 30 days following completion of different oral LFF571 dose regimens (cohort 2) | 30 days |
| POC: To evaluate the fecal concentrations of LFF571 following different LFF571 dose regimens (cohort 2) | 30 days |
| POC: To evaluate the serum concentrations of LFF571 following different LFF571 dose regimens. (cohort 2) | 30 days |
| Cohort 2: Time to resolution of diarrhea during the treatment period for oral LFF571 in C. difficile infected patients. | Day 12/13 |
| Cohort 2: Serum concentrations of oral LFF571 following different dose regimens in C. difficile infected patients. | Day 12/13 |
| Cohort 2: Fecal concentrations of LFF571 following different oral LFF571 dose regimens in C. Difficile infected patients. | Day 12/13 |
| Cohort 2: Sustained response (sustained clinical cure) rate and clinical relapse rate at 30 days following completion of different oral LFF571 dose regimens. | Clinical cure is resolution or improvement of symptoms and signs of C. difficile infection such that additional or alternative antimicrobial therapy or other theraperutic intervention is not needed. In addition, patient must have absence of fever for two consecutive days and <3 non-lliquid stools per day for two consecutive days | 30 days |
| Bristol |
| Connecticut |
| 06010 |
| United States |
| Novartis Investigative Site | Clearwater | Florida | 33756 | United States |
| Novartis Investigative Site | Decatur | Georgia | 30030 | United States |
| Novartis Investigative Site | Idaho Falls | Idaho | 83404 | United States |
| Novartis Investigative Site | Chicago | Illinois | 60637 | United States |
| Novartis Investigative Site | Michigan City | Indiana | 46360 | United States |
| Novartis Investigative Site | Topeka | Kansas | 66606 | United States |
| Novartis Investigative Site | Butte | Montana | 59701 | United States |
| Novartis Investigative Site | Durham | North Carolina | 27710 | United States |
| Novartis Investigative Site | Columbus | Ohio | 43215 | United States |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73112 | United States |
| Novartis Investigative Site | Charleston | South Carolina | 29425 | United States |
| Novartis Investigative Site | San Antonio | Texas | 78212 | United States |
| Novartis Investigative Site | Hamilton | Ontario | L8N 4A6 | Canada |
| Novartis Investigative Site | Chicoutimi | Quebec | G7H 5H6 | Canada |
| Novartis Investigative Site | Montreal | Quebec | H1T 2M4 | Canada |
| Novartis Investigative Site | Trois-Rivières | Quebec | G8Z 3R9 | Canada |
| Bhansali SG, Mullane K, Ting LS, Leeds JA, Dabovic K, Praestgaard J, Pertel P. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar;59(3):1441-5. doi: 10.1128/AAC.04252-14. Epub 2014 Dec 22. |
| ID | Term |
|---|---|
| D004761 | Enterocolitis, Pseudomembranous |
| ID | Term |
|---|---|
| D003015 | Clostridium Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D004760 | Enterocolitis |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C573298 | LFF571 |
| D014640 | Vancomycin |
| ID | Term |
|---|---|
| D006020 | Glycopeptides |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided